Sargafusal, a rare norsesquiterpenoid from the edible brown alga Sargassum fusiforme

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-02-19 DOI:10.1016/j.phytol.2025.02.008

Junzhi Pan , Guohao Hu , Feijing Lv , Zhongyang Shi , Wuming Dong , Yu Qi , Chaojie Wang , Haibing Tong , Fangjian Huang , Pengcheng Yan

{"title":"Sargafusal, a rare norsesquiterpenoid from the edible brown alga Sargassum fusiforme","authors":"Junzhi Pan , Guohao Hu , Feijing Lv , Zhongyang Shi , Wuming Dong , Yu Qi , Chaojie Wang , Haibing Tong , Fangjian Huang , Pengcheng Yan","doi":"10.1016/j.phytol.2025.02.008","DOIUrl":null,"url":null,"abstract":"<div><div>A previously undescribed C14-norsesquiterpenoid aldehyde with a hexahydrobenzofuran scaffold, sargafusal (1), was isolated from an EtOAc-soluble extract of the edible brown alga Sargassum fusiforme, together with three known norisoprenoids (2–4). The chemical structure of sargafusal (1) was established by extensive spectroscopic analyses, including 1D and 2D NMR, ECD and DFT-calculated ECD, and HR-ESI-MS data. Sargafusal (1) represents the first C14-norsesquiterpenoid aldehyde from the family Sargassaceae. Compounds 1, 3, and 4 showed potent antioxidant neuroprotective effects against H2O2-induced oxidative damage in neuron-like PC12 cells. This study provides new insight into the drug discovery efforts on the promising neuroprotective lead compounds from marine algae resource.</div></div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"66 ","pages":"Pages 86-90"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874390025010201","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

A previously undescribed C₁₄-norsesquiterpenoid aldehyde with a hexahydrobenzofuran scaffold, sargafusal (1), was isolated from an EtOAc-soluble extract of the edible brown alga Sargassum fusiforme, together with three known norisoprenoids (2–4). The chemical structure of sargafusal (1) was established by extensive spectroscopic analyses, including 1D and 2D NMR, ECD and DFT-calculated ECD, and HR-ESI-MS data. Sargafusal (1) represents the first C₁₄-norsesquiterpenoid aldehyde from the family Sargassaceae. Compounds 1, 3, and 4 showed potent antioxidant neuroprotective effects against H₂O₂-induced oxidative damage in neuron-like PC12 cells. This study provides new insight into the drug discovery efforts on the promising neuroprotective lead compounds from marine algae resource.

查看原文本刊更多论文

马尾藻，一种罕见的北倍半萜，来自可食用的褐藻马尾藻

先前描述的c14 -壬倍半萜类醛与六氢苯并呋喃支架，sargafal(1)，是从可食用褐藻马尾藻（Sargassum fusiforme）的etoac可溶性提取物中分离出来的，连同三种已知的类壬异戊二烯（2-4）。通过广泛的光谱分析，包括1D和2D NMR， ECD和dft计算ECD以及HR-ESI-MS数据，确定了sargafsal(1)的化学结构。马尾草(1)是马尾草科第一个c14 -去倍半萜醛。化合物1、3和4对h2o2诱导的神经元样PC12细胞的氧化损伤具有有效的抗氧化神经保护作用。本研究为海洋藻类资源中具有神经保护作用的先导化合物的药物开发提供了新的思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.